Published in J Exp Med on May 01, 1981
Tumor-promoting phorbol esters stimulate C3b and C3b' receptor-mediated phagocytosis in cultured human monocytes. J Exp Med (1982) 7.10
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med (1982) 4.96
Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 3.57
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci U S A (2002) 2.95
Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med (1986) 2.94
Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med (1984) 2.53
Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci U S A (1983) 2.30
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J (1983) 1.94
Purification and structural studies on the complement-system control protein beta 1H (Factor H). Biochem J (1982) 1.91
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci U S A (1985) 1.81
Functional properties of membrane cofactor protein of complement. Biochem J (1989) 1.68
Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3. J Exp Med (1985) 1.57
Structural heterogeneity of the C3b/C4b receptor (Cr 1) on human peripheral blood cells. J Exp Med (1983) 1.43
Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c. Proc Natl Acad Sci U S A (1982) 1.33
Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med (1995) 1.26
Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J Exp Med (1984) 1.23
Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med (1988) 1.21
Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. J Exp Med (1991) 1.18
Characterization of three monoclonal antibodies against C3 with selective specificities. Immunology (1987) 1.17
Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med (1989) 1.15
Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex. Biochem J (1983) 1.14
Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Proc Natl Acad Sci U S A (1986) 1.14
Effect of human serum and some of its components on neutrophil adherence and migration across an epithelium. J Cell Biol (1986) 1.14
Mapping epitopes for 20 monoclonal antibodies to CR1. Clin Exp Immunol (1998) 1.12
Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol (1997) 1.10
Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions. Clin Exp Immunol (1988) 1.06
Biosynthesis of the human C3b/C4b receptor during differentiation of the HL-60 cell line. Identification and characterization of a precursor molecule. J Clin Invest (1984) 1.06
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica (2013) 1.04
Leishmania major-human macrophage interactions: cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion. Infect Immun (1996) 1.03
Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes. Blood (2011) 1.02
Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol (1986) 1.01
Interaction of C4-binding protein with cell-bound C4b. A quantitative analysis of binding and the role of C4-binding protein in proteolysis of cell-bound C4b. J Exp Med (1983) 1.01
Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest (1985) 1.01
gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. Immunology (1988) 1.00
Evidence for linkage between the loci coding for the binding protein for the fourth component of human complement (C4BP) and for the C3b/C4b receptor. Proc Natl Acad Sci U S A (1984) 0.99
Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells. J Virol (1985) 0.98
The role of complement, platelet-activating factor and leukotriene B4 in a reversed passive Arthus reaction. Br J Pharmacol (1992) 0.98
Large-scale isolation of complement receptor type 1 (CR1) from human erythrocytes. Proteolytic fragmentation studies. Biochem J (1985) 0.97
Enzymic assay of C3b receptor on intact cells and solubilized cells. Biochem J (1983) 0.97
Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest (1989) 0.96
Quantitative variations of the C3b/C4b receptor (CR1) in human erythrocytes are controlled by genes within the regulator of complement activation (RCA) gene cluster. J Exp Med (1986) 0.92
The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J Virol (2009) 0.92
Polymorphism and proteolytic fragments of granulocyte membrane cofactor protein (MCP, CD46) of complement. Biochem J (1992) 0.89
Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H. Proc Natl Acad Sci U S A (1987) 0.88
CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes. Immunology (2001) 0.85
Soluble C3 proconvertase and convertase of the classical pathway of human complement. Conditions of stabilization in vitro. Biochem J (1985) 0.81
Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor. Immunology (1989) 0.81
Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line. Immunology (1995) 0.81
Membrane-bound C4b interacts endogenously with complement receptor CR1 of human red cells. J Exp Med (1986) 0.80
A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1). Clin Exp Immunol (1987) 0.80
Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo) (2012) 0.80
Soluble human complement receptor type 1 inhibits complement-mediated host defense. Clin Diagn Lab Immunol (1994) 0.79
Identification of a complement receptor 1 peptide for inhibition of immune hemolysis. Biochem Biophys Res Commun (2006) 0.79
Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood. Mol Immunol (2011) 0.78
In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes. Ann Rheum Dis (1989) 0.78
Clonal variations in complement activation and deposition of C3b and C4b on model immune complexes. Immunology (1993) 0.78
Development of complement therapeutics for inhibition of immune-mediated red cell destruction. Transfusion (2005) 0.78
The change in C3b receptors on erythrocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (1985) 0.78
Complement receptor 1 genetic variants contribute to the susceptibility to gastric cancer in chinese population. J Cancer (2015) 0.76
An exon-based comparative variant analysis pipeline to study the scale and role of frameshift and nonsense mutation in the human-chimpanzee divergence. Comp Funct Genomics (2009) 0.76
Role of complement receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney. Mol Immunol (2015) 0.75
Receptors for complement components in inflammation. Agents Actions (1983) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med (1970) 15.86
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Receptors for complement of leukocytes. J Exp Med (1968) 11.57
The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science (1953) 9.02
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry (1976) 7.80
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 6.49
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res (1968) 6.20
The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 6.19
Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med (1972) 6.13
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 5.08
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
Properties of highly purified human properdin. J Immunol (1968) 3.96
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Immune adherence by the fourth component of complement. Science (1969) 3.34
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Specificity of human lymphocyte complement receptors. J Exp Med (1975) 2.77
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science (1976) 2.70
The isolation and structure of C4, the fourth component of human complement. Biochem J (1977) 2.61
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Mechanism of action of the C3b inactivator: requirement for a high molecular weight cofactor (C3b-C4bINA cofactor) and production of a new C3b derivative (C3b'). Immunochemistry (1978) 2.43
A receptor for the third component of complement in the human renal glomerulus. J Exp Med (1975) 2.39
Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b. Proc Natl Acad Sci U S A (1977) 2.27
Cleavage products of C4b produced by enzymes in human serum. Immunochemistry (1975) 2.26
Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol (1977) 2.16
Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5. J Immunol (1974) 1.73
The fifth component of the guinea pig complement system. II. Mechanism of SAC1,4,2,3,5b formation and C5 consumption by EAC1,4,2,3. J Immunol (1971) 1.34
Reaction mechanisms of beta1H globulin. Int Arch Allergy Appl Immunol (1978) 1.24
The fifth component of the guinea pig complement system. 3. Dissociation and transfer of C5b, and the probable site of C5b fixation. J Immunol (1971) 1.18
Ox erythrocyte agglutinability. 1. Variation in the membrane protein. Vox Sang (1970) 1.09
A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med (1970) 15.86
Receptors for complement of leukocytes. J Exp Med (1968) 11.57
Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc Natl Acad Sci U S A (1983) 8.57
Binding of sheep red blood cells to a large population of human lymphocytes. Nature (1971) 7.67
The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 6.19
Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med (1972) 6.13
Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood (1973) 4.99
Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med (1982) 4.96
Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med (1980) 4.81
TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell (1997) 4.65
Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature (1989) 4.08
Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo) (1996) 3.97
A new complement function: solubilization of antigen-antibody aggregates. Proc Natl Acad Sci U S A (1975) 3.97
Migration of Plasmodium sporozoites through cells before infection. Science (2001) 3.89
Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science (1980) 3.71
Ca++-dependent binding of antigen-19 S antibody complexes to macrophages. J Immunol (1969) 3.70
Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med (1986) 3.68
Studies on the mechanism of solubilization of immune precipitates by serum. J Exp Med (1976) 3.68
Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature (1987) 3.62
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med (1985) 3.33
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med (1982) 3.26
Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science (1985) 3.24
Theta-bearing and complement-receptor lymphocytes are distinct populations of cells. Science (1971) 3.16
Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med (1983) 3.07
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Electron microscopic studies on mode of action of polymyxin. J Bacteriol (1969) 2.97
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med (1987) 2.86
The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell (1992) 2.78
Monoclonal antibodies to circumsporozoite proteins identify the species of malaria parasite in infected mosquitoes. Nature (1982) 2.76
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
Cofilin is a component of intranuclear and cytoplasmic actin rods induced in cultured cells. Proc Natl Acad Sci U S A (1987) 2.70
Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med (1993) 2.60
Structure of the plasmodium knowlesi gene coding for the circumsporozoite protein. Cell (1983) 2.60
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science (1987) 2.59
Phosphorylation of Ser-3 of cofilin regulates its essential function on actin. Genes Cells (1996) 2.52
Cell surface immunoglobulin. IV. Distribution among thymocytes, bone mrrow cells, and their derived populations. J Exp Med (1972) 2.50
Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature (1997) 2.49
Human lymphocytes bear membrane receptors for C3b and C3d. J Clin Invest (1973) 2.46
Circumsporozoite proteins of malaria parasites. Cell (1985) 2.45
Conservation of a gliding motility and cell invasion machinery in Apicomplexan parasites. J Cell Biol (1999) 2.43
Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol (1999) 2.41
Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science (1985) 2.41
Research toward malaria vaccines. Science (1986) 2.40
Inhibition of the interactions of cofilin, destrin, and deoxyribonuclease I with actin by phosphoinositides. J Biol Chem (1990) 2.35
Antihapten antibody specificity and L chain type. J Exp Med (1967) 2.33
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci U S A (1983) 2.30
Tissue localization of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. Proc Natl Acad Sci U S A (1970) 2.29
Complement-dependent release of immune complexes from the lymphocyte membrane. J Exp Med (1973) 2.27
Stage-specific surface antigens expressed during the morphogenesis of vertebrate forms of Trypanosoma cruzi. Exp Parasitol (1987) 2.25
Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood (1972) 2.25
Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. J Clin Invest (1978) 2.24
Receptors for immune complexes on lymphocytes. Adv Immunol (1974) 2.23
Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol (1987) 2.19
Ubiquity of the repetitive epitope of the CS protein in different isolates of human malaria parasites. J Immunol (1985) 2.09
Polyphosphoinositide micelles and polyphosphoinositide-containing vesicles dissociate endogenous gelsolin-actin complexes and promote actin assembly from the fast-growing end of actin filaments blocked by gelsolin. J Biol Chem (1987) 2.08
Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother (1998) 2.07
A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell (1991) 2.04
Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med (1981) 2.02
The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J Exp Med (1979) 1.97
Selective phagocytic paralysis induced by immobilized immune complexes. J Exp Med (1975) 1.96
Two mammalian heat shock proteins, HSP90 and HSP100, are actin-binding proteins. Proc Natl Acad Sci U S A (1986) 1.93
Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ (1979) 1.92
Dental pulp cells for induced pluripotent stem cell banking. J Dent Res (2010) 1.92
Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature (1983) 1.90
Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein. Nature (1983) 1.90
Structural and functional properties of Trypanosoma trans-sialidase. Annu Rev Microbiol (1994) 1.89
Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med (1986) 1.88
Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci U S A (1985) 1.87
Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med (1978) 1.85
Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J Med Virol (2000) 1.84
Complement as a regulator of interactions between immune complexes and cell membranes. J Immunol (1974) 1.83
Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proc Natl Acad Sci U S A (1982) 1.82
Cell wall alterations of gram-negative bacteria by aminoglycoside antibiotics. Antimicrob Agents Chemother (1974) 1.81
Bone marrow origin of complement-receptor lymphocytes. Eur J Immunol (1971) 1.80
Mechanism of solubilization of immune aggregates by complement. Implications for immunopathology. Transplant Rev (1976) 1.80
Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes. J Exp Med (1977) 1.79
Identification of a polyphosphoinositide-modulated domain in gelsolin which binds to the sides of actin filaments. J Cell Biol (1988) 1.76
Specificity of the antibodies produced by single cells following immunization with antigens bearing two types of antigenic determinants. J Exp Med (1967) 1.75
Structural and functional properties of region II-plus of the malaria circumsporozoite protein. J Exp Med (1994) 1.75
The exit of Trypanosoma cruzi from the phagosome is inhibited by raising the pH of acidic compartments. J Exp Med (1990) 1.64
Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells. J Immunol (1982) 1.63
Exploring the transcriptome of the malaria sporozoite stage. Proc Natl Acad Sci U S A (2001) 1.59
Synthetic peptide vaccine confers protection against murine malaria. J Exp Med (1987) 1.58
The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med (1987) 1.55
Occurrence of caldesmon (a calmodulin-binding protein) in cultured cells: comparison of normal and transformed cells. Proc Natl Acad Sci U S A (1984) 1.53
Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5. J Biol Chem (1997) 1.52
Purificaiton and characterization of mouse serum protein with specific binding affinity for C4 (Ss protein). J Exp Med (1977) 1.50
Attachment of Trypanosoma cruzi to mammalian cells requires parasite energy, and invasion can be independent of the target cell cytoskeleton. Infect Immun (1991) 1.50
A glycan-phosphatidylinositol-specific phospholipase D in human serum. Science (1987) 1.50
Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child (2000) 1.50
Characterization of a novel trypanosome lytic factor from human serum. Infect Immun (1999) 1.49